Diabetic foot ulcers can be extremely challenging to treat and are associated with a high
morbidity and mortality.
A recent large randomised controlled trial (RCT), found that a single application of a fetal bovine acellular dermal matrix in combination with
standard of care (SOC) is a faster and more effective treatment for these ulcers than SOC alone*.

In this masterclass, the RCT investigators will discuss the evidence, and explore the
implications for practice with other clinicians who have used the dermal scaffold. The debate
will focus on how to optimise the use of this technology on this wound type.

Meet our Speakers

John C. Lantis II

Mount Sinai West Hospital

Chief of Surgery

Robert J. Snyder

Barry University School of Podiatric Medicine

Professor & Director of Clinical Research

Thomas Nicholas

South Mersey Arterial Centre & Warrington and Halton Teaching Hospitals

Consultant Vascular Surgeon

Kate Merriman

Shrewsbury and Telford Hospitals

Consultant Vascular Surgeon

Meet our Sponsor

Integra LifeSciences is a global leader in regenerative medicine.

With widely recognized brands, our Tissue Technologies division offers a comprehensive portfolio of solutions to address a wide range of clinical conditions, including acute and chronic wounds, burns, oncological lesions, nerve lesions, breast and abdominal wall reconstruction.

*Lantis et al., JWC, 2021


Subscribe to the Journal of Wound Care today! The leading monthly journal for nurses, medics and researchers working in wound care.

JWC is essential reading for wound care professionals who are serious about providing the best possible support for the people in their care, and those who want to keep on top of the latest thinking and research.

Contact Us

Anthony Kerr

Managing Director, MA Healthcare Ltd.


+44 (0) 207 501 6726

Emma Blick

Commercial Manager



Tracy Cowan

Associate Publisher, Projects Programme Planner


+44 (0) 207 501 6717

Events team

General enquiries